Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis~* Male and female subjects, aged at least 18 years, with newly-diagnosed or relapsed associated vasculitis (AAV) where treatment with cyclophosphamide or rituximab is needed; where approved by Regulatory Agencies, adolescents (12-17 year old) may be enrolled~* Use of adequate contraception~* Positive test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO)~* At least 1 major item, or at least 3 non-major items, or at least the 2 renal items of proteinuria and hematuria on Birmingham Vasculitis Activity Score (BVAS)~* Estimated glomerular filtration rate ≥15 mL/minute/1.73 m\^2 at screening~Exclusion Criteria:~* Pregnant or breast-feeding~* Alveolar hemorrhage requiring pulmonary ventilation support at screening~* Any other known multi-system autoimmune disease~* Required dialysis or plasma exchange within 12 weeks prior to screening~* Have a kidney transplant~* Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1~* Received intravenous glucocorticoids, \>3000 mg methylprednisolone equivalent, within 4 weeks prior to screening~* Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening~* Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count \> 0.01x10\^9/L); received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening~* For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, active infection (especially varicella zoster infection), or platelet count \<50,000/μL before start of dosing~* Participated previously in a CCX168 study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone group (Type: ACTIVE_COMPARATOR): Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
- Avacopan group (Type: EXPERIMENTAL): Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).